Журнал "Почки" том 9, №1

Îðèã³íàëüí³ ñòàòò³ / Original Articles
portunities. Rev. Recent. Clin. Trials. 2018. 13(3). Р. 192-198. doi:
10.2174/1574887113666180314091831.
7. Taraborelli M., Sciatti E., Bonadei I., Terlizzi V., Fredi M.,
Zani R. et al. Endothelial Dysfunction in Early Systemic Lupus Erythematosus
Patients and Controls Without Previous Cardiovascular
Events. Arthritis Care Res (Hoboken). 2018. 70(9). Р. 1277-1283.
doi: 10.1002/acr.23495.
8. Mak A., Kow N.Y., Schwarz H., Gong L., Tay S.H., Ling L.H.
Endothelial dysfunction in systemic lupus erythematosus — a casecontrol
study and an updated meta-analysis and meta-regression. Sci.
Rep. 2017. 7(1). Р. 7320. doi: 10.1038/s41598-017-07574-1.
9. Nawata A., Hisano S., Shimajiri S., Wang K.Y., Tanaka Y.,
Nakayama T. Podocyte and endothelial cell injury lead to nephrotic
syndrome in proliferative lupus nephritis. Histopathology. 2018. 72(7).
P. 1084-1092. doi: 10.1111/his.13454.
10. Yuan M., Tan Y., Wang Y., Wang S.X., Yu F., Zhao M.H.
The associations of endothelial and podocyte injury in proliferative
lupus nephritis: from observational analysis to in vitro study. Lupus.
2019. 28(3). P. 347-358. doi: 10.1177/0961203319828509.
11. Deng W., Xu M., Meng Q., Li Z., Qiu X., Yin S. et al.
CD8+CD103+ iTregs inhibit the progression of lupus nephritis by attenuating
glomerular endothelial cell injury. Rheumatology (Oxford).
2019. 58(11). Р. 2039-2050. doi: 10.1093/rheumatology/kez112.
12. Dimou P., Wright R.D., Budge K.L., Midgley A., Satchell S.C.,
Peak M. et al. The human glomerular endothelial cells are potent proinflammatory
contributors in an in vitro model of lupus nephritis. Sci.
Rep. 2019. 9(1). P. 8348. doi: 10.1038/s41598-019-44868-y.
13. Hochberg M.C. Updating the American College of Rheumatology
revised criteria for the classification of systemic lupus
erythematosus. Arthritis Rheum. 1997. 40(9). P. 1725. doi:
10.1002/1529-0131(199709)40:9<1725::aid-art29>3.0.co;2-y.
14. Kovalenko V.M., Shuba N.M., Gajko G.V. Nomenclature,
classification, diagnostic criteria and treatment programs for rheumatic
diseases. Ukrainian Association of Rheumatologists, Ukrainian
Association of Orthopaedists and Traumatologists. Kyiv, 2004. P. 156.
(In Ukrainian).
15. Celermajer D.S., Sorensen K.E., Bull C., Robinson J., Deanfield
J.E. Endothelium-dependent dilation in the systemic arteries of
asymptomatic subjects relates to coronary risk factors and their interaction.
J. Amer. Coll. Cardiology. 1994. 24(6). P. 1468-1474. doi:
10.1016/0735-1097(94)90141-4.
16. Voronenko Ju.V., Moskalenko V.F. Social medicine and
health care organization. Ternopil’: Ukrmedknyga, 2000. P. 680. (In
Ukrainian).
17. Bjujul’ A., Cëfel’ P. SPSS: the art of processing information.
Transl. from German. Moscow, 2005. P. 608. (In Russian).
18. Caraba A., Savoiu G., Crisan V. Endothelial dysfunction in
systemic lupus erythematosus. Romanian J. Biophys. 2008. 18(3).
P. 237-244.
19. El Magadmi M., Bodill H., Ahmad Y., Durrington P.N.,
Mackness M., Walker M. et al. Systemic lupus erythematosus:
an independent risk factor for endothelial dysfunction in women.
Circulation. 2004. 110(4). P. 399-404. doi: 10.1161/01.
CIR.0000136807.78534.50.
20. Lima D.S., Lima V.C., Miranda F. Jr, Hatta F.H. Brachial
endothelial function is impaired in patients with systemic lupus erythematosus.
J. Rheumatol. 2002. 29(2). P. 292-297. PMID: 11842823.
21. Piper M.K., Raza K., Nuttal S.L., Stevens R., Toescu V., Heaton
S. et al. Impaired endothelial function in systemic lupus erythematosus.
Lupus. 2007. 16(2). P. 84-88. doi: 10.1177/0961203306074842.
22. Falaschi F., Revelli A., Martignoni A., Migliavacca D., Sartori
M., Pistorio A. et al. Nephrotic-range proteinuria, the major risk
factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus.
Arthritis Rheum. 2000. 43(6). P. 1405-1409.
23. Frostegard J., Svenungsson E., Wu R., Gunnarsson I.,
Lundberg I.E., Klareskoq L. et al. Lipid peroxidation is enhanced in
patients with systemic lupus erythematosus and is associated with arterial
and renal disease manifestations. Arthritis Rheum. 2005. 52(1).
P. 192-200. doi: 10.1002/art.20780.
24. Karadag O., Calguneri M., Atalar E., Yavuz B. Novel cardiovascular
risk factors and cardiac event predictors in female inactive
systemic lupus erythematosus patients. Clin. Rheumatol. 2007. 26.
P. 695-699. doi: 10.1007/s10067-006-0376-1.
25. Wright S.A., O’Prey F.M., Rea D.J., Plumb R.D., Gamble
A.G., Leahey W.J. et al. Microcirculatory hemodynamics and
endothelial dysfunction in systemic lupus erythematosus. Arteriosclerosis,
Thrombosis, and Vascular Biology. 2006. 26(10). P. 2281-2287.
doi: 10.1161/01.ATV.0000238351.82900.7f.
Отримано/Received 04.01.2020
Рецензовано/Revised 27.01.2020
Прийнято до друку/Accepted 29.01.2020
Information about authors
I.G. Matiyashchuk, MD, PhD, Doctor of Rheumatology Department 1, Alexander’s Clinical Hospital, Kyiv, Ukraine; e-mail: irina_doc@ukr.net; ORCID: https://orcid.org/0000-0003-1328-0569
K.M. Amosova, MD, Professor, Bogomolets National Medical University, Kyiv, Ukraine; e-mail: kateryna.amosova@gmail.com; ORCID: https://orcid.org/0000-0002-4570-9510
O.B. Iaremenko, MD, Professor, Head of the Department of Internal Medicine 3, Bogomolets National Medical University, Kyiv, Ukraine; e-mail: o.b.iaremenko@gmail.com; ORCID: https://orcid.org/0000-
0003-2095-5819
V.I. Zaсharova, МD, Сardiologist of Neurosurgeon department, Alexander’s Clinical Hospital, Kyiv, Ukraine; e-mail: val0970660077@gmail.com; ORCID: https://orcid.org/0000-0002-3639-0333
D.I. Koliadenko, PhD student, Assistant professor at the Department of Internal Medicine 3, Bogomolets National Medical University, Kyiv, Ukraine; e-mail: daria.koliadenko@gmail.com; ORCID: https://
orcid.org/0000-0002-9562-9367
Ìàòèÿùóê È.Ã., Àìîñîâà Å.Í., ßðåìåíêî Î.Á., Çàõàðîâà Â.È., Êîëÿäåíêî Ä.È.
Íàöèîíàëüíûé ìåäèöèíñêèé óíèâåðñèòåò èìåíè À.À. Áîãîìîëüöà, ã. Êèåâ, Óêðàèíà
Íàðóøåíèå âàçîðåãóëèðóþùåé ôóíêöèè ýíäîòåëèÿ ó áîëüíûõ ñèñòåìíîé êðàñíîé âîë÷àíêîé:
àññîöèàöèÿ ñ ïîðàæåíèåì ïî÷åê, ìàðêåðàìè âîñïàëåíèÿ è àóòîàíòèòåëàìè
Резюме. Актуальность. Ведущей причиной смертности у за считается нарушение функции эндотелия. Цель работы:
больных системной красной волчанкой (СКВ) являются оценить состояние вазорегулирующей функции эндотелия у
сердечно-сосудистые заболевания вследствие раннего атеросклероза.
Одним из маркеров субклинического атеросклероностями
СКВ. Материалы и методы. Проведено
больных СКВ и ее связь с клинико-лабораторными особен-
определение
Òîì 9, ¹ 1, 2020
www.mif-ua.com, http://kidneys.zaslavsky.com.ua 29